TXG
10x Genomics, Inc.
NASDAQ · USHealthcareMedical - Healthcare Information Services
$43.22-1.19%
Price as of Jul 20, 2026
TXG financials
10x Genomics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $642.8M | $610.8M | $618.7M | $516.4M |
| Cost of revenue | $198.9M | $196.3M | $209.4M | $120.4M |
| Gross profit | $443.9M | $414.5M | $409.3M | $396.0M |
| Operating expenses | $554.8M | $609.0M | $674.6M | $564.0M |
| Operating income | -$110.9M | -$194.6M | -$265.3M | -$167.9M |
| Net income | -$43.5M | -$182.6M | -$255.1M | -$166.0M |
| EBITDA | $3.9M | -$134.0M | -$205.1M | -$128.5M |
| Basic EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 |
| Diluted EPS | $-0.35 | $-1.52 | $-2.18 | $-1.46 |
| Balance sheet | ||||
| Cash & equivalents | $474.0M | $344.1M | $359.3M | $219.7M |
| Total assets | $1.0B | $918.6M | $965.1M | $1.0B |
| Total liabilities | $245.0M | $208.5M | $224.1M | $223.2M |
| Stockholders’ equity | $796.3M | $710.1M | $741.0M | $805.7M |
| Total debt | $157.7M | $82.6M | $95.4M | $95.2M |
| Net debt | -$316.2M | -$261.5M | -$263.9M | -$124.6M |
| Cash flow | ||||
| Operating cash flow | $136.1M | $6.7M | -$15.2M | -$33.6M |
| Capital expenditure | -$5.9M | -$12.4M | -$49.5M | -$131.7M |
| Free cash flow | $130.1M | -$5.7M | -$64.7M | -$165.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |